ReviewHuman molecular genetics2011
Genetic therapies for cystic fibrosis lung disease.
Review in Human molecular genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Gene Therapy for Respiratory Diseases: Progress and a Changing Context.Human gene therapy · 2020Article
- Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Lentiviral-mediated phenotypic correction of cystic fibrosis pigs.JCI insight · 2016Article
- Human, Pig, and Mouse Interferon-Induced Transmembrane Proteins Partially Restrict Pseudotyped Lentiviral Vectors.Human gene therapy · 2016Article
- In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection.Human gene therapy · 2014Article
- Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2014Article
- Nanotechnology approaches for inhalation treatment of fibrosis.Journal of drug targeting · 2013Review
- Intrapulmonary Versus Nasal Transduction of Murine Airways With GP64-pseudotyped Viral Vectors.Molecular therapy. Nucleic acids · 2013Article
- Lentiviral vector gene transfer to porcine airways.Molecular therapy. Nucleic acids · 2012Article
- Transcriptional targeting in the airway using novel gene regulatory elements.American journal of respiratory cell and molecular biology · 2012Article
- Gene therapy for the treatment of cystic fibrosis.The application of clinical genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The aim of gene therapy for cystic fibrosis (CF) lung disease is to efficiently and safely express the CF transmembrane conductance regulator (CFTR) in the appropriate pulmonary cell types. Although CF patients experience multi-organ disease, the chronic bacterial lung infections and associated inflammation are the primary cause of shortened life expectancy. Gene transfer-based therapeutic approaches are feasible, in part, because the airway epithelium is directly accessible by aerosol delivery or instillation. Improvements in standard delivery vectors and the development of novel vectors, as well as emerging technologies and new animal models, are propelling exciting new research forward. Here, we review recent developments that are advancing this field of investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.